NCT03702361View on ClinicalTrials.gov

Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

March 18, 2021

Conditions
Primary Disease
Interventions
DRUG

VPRIV

VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Trial Locations (1)

9103102

Michal Becker- Cohen, Jerusalem

All Listed Sponsors
lead

Shaare Zedek Medical Center

OTHER

NCT03702361 - Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease | Biotech Hunter | Biotech Hunter